| Schedule of patents |
| | | Useful life | | | December 31, 2019 | | | June 30, 2019 | | | | | | | | | | | | | Purchased Patent Rights- Brilacidin, and related compounds | | | 14 | | | $ | 4,082,000 | | | $ | 4,082,000 | | Purchased Patent Rights-Anti-microbial- surfactants and related compounds | | | 12 | | | | 144,000 | | | | 144,000 | | Patents - Kevetrin and related compounds | | | 17 | | | | 1,163,000 | | | | 1,118,000 | | | | | | | | | 5,389,000 | | | | 5,344,000 | | Less: Accumulated amortization for Brilacidin, Anti-microbial- surfactants and related compounds | | | | | | | (1,917,000 | ) | | | (1,765,000 | ) | Accumulated amortization for Patents-Kevetrin and related compounds | | | | | | | (271,000 | ) | | | (237,000 | ) | Total | | | | | | $ | 3,201,000 | | | $ | 3,342,000 | |
|